MedTrace Logo

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

NCT04262830 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-01-28

No results posted yet for this study

Summary

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac magnetic resonance imaging (MRI)

Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics

OTHER

Accelerometer physical activity monitoring

Measurement of physical activity using hip-worn accelerometer.

Sponsors & Collaborators

  • Hari Narayan

    lead OTHER

Principal Investigators

  • Hari Narayan, MD · University of California San Diego, Rady Children's Hospital

Eligibility

Min Age
13 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2028-09-30
Completion
2030-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04262830 on ClinicalTrials.gov